4//SEC Filing
Rolke James 4
Accession 0000920465-20-000039
CIK 0000920465other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 4:14 PM ET
Size
7.0 KB
Accession
0000920465-20-000039
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-02-28+142→ 142 totalExercise: $6.80Exp: 2030-02-28→ Common Stock (142 underlying) - Award
Common Stock
2020-02-28$5.78/sh+142$821→ 80,677 total
Footnotes (2)
- [F1]These shares were acquired on 02/28/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Documents
Issuer
LA JOLLA PHARMACEUTICAL CO
CIK 0000920465
Entity typeother
Related Parties
1- filerCIK 0001693858
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 4:14 PM ET
- Size
- 7.0 KB